Insider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) CEO Sells 25,000 Shares of Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 25,000 shares of the business’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $51.60, for a total value of $1,290,000.00. Following the completion of the transaction, the chief executive officer now directly owns 257,054 shares in the company, valued at approximately $13,263,986.40. This represents a 8.86 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

David Alan Campbell also recently made the following trade(s):

• On Monday, October 28th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The stock was sold at an average price of $53.54, for a total value of $1,338,500.00.
• On Friday, September 27th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The stock was sold at an average price of $46.31, for a total transaction of $1,157,750.00.

Janux Therapeutics Price Performance

JANX stock traded down $1.61 during mid-day trading on Wednesday, reaching $46.39. 649,812 shares of the company traded hands, compared to its average volume of 710,287. Janux Therapeutics, Inc. has a 52-week low of $7.79 and a 52-week high of $65.60. The company has a market capitalization of $2.43 billion, a P/E ratio of -39.65 and a beta of 3.52. The company has a fifty day moving average price of $50.02 and a 200-day moving average price of $45.82.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The firm had revenue of $0.44 million for the quarter, compared to analysts’ expectations of $1.50 million. The business’s quarterly revenue was down 82.6% on a year-over-year basis. As a group, analysts forecast that Janux Therapeutics, Inc. will post -1.35 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in Janux Therapeutics by 38.6% in the first quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after acquiring an additional 378,477 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new stake in Janux Therapeutics in the 1st quarter worth approximately $739,000. Artal Group S.A. purchased a new stake in Janux Therapeutics in the first quarter worth approximately $1,882,000. Virtu Financial LLC purchased a new position in shares of Janux Therapeutics during the first quarter worth approximately $609,000. Finally, DNB Asset Management AS bought a new stake in shares of Janux Therapeutics in the 2nd quarter worth approximately $221,000. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. Wedbush reissued an “outperform” rating and set a $74.00 target price on shares of Janux Therapeutics in a research report on Thursday, August 8th. HC Wainwright reissued a “buy” rating and issued a $63.00 target price on shares of Janux Therapeutics in a research report on Thursday, November 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $100.00 price target on shares of Janux Therapeutics in a research report on Thursday, November 7th. Leerink Partnrs raised Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. Finally, Stifel Nicolaus assumed coverage on shares of Janux Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $70.00 price objective on the stock. One research analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $67.70.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.